Document:

<PAGE>

                                                                   EXHIBIT 10.29

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                    WITH THE SECURITIES AND EXCHANGE COMMISSION.
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(B)(4)
                                                                  AND 240.24b-2.

April 25, 2002

Mr. Brad Crawford
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

RE: AMENDMENT NO. 1 TO AMGEN/INTERMUNE LICENSE AND COMMERCIALIZATION AGREEMENT
    FOR INFERGEN

Dear Mr. Crawford:

Our signatures below approve this document as Amendment No. 1 ("Amendment") to
that certain License and Commercialization Agreement, dated as of June 15, 2001,
between Amgen Inc. ("Amgen") and InterMune, Inc. ("InterMune") (the
"Agreement"). Amgen and InterMune shall be collectively referenced herein as the
"Parties."

For good and valuable consideration, the receipt of which is hereby
acknowledged, the Parties hereby agree as follows:

1. The second sentence of Section 1.27 of the Agreement (definition of Licensed
Product) is hereby deleted in its entirety and amended and superseded as
follows:

     "Licensed Products include but are not limited to Infergen and PEG-Infergen
     Products."

2. The following shall be added to the last sentence of Section 3.3 of the
Agreement:

     ", and such PEG-Infergen Product shall be [***]"

3. The following shall be added to the last sentence of Section 5.2(b) of the
Agreement:

     ", and such PEG-Infergen Product shall be [***]"

4. The first sentence of Section 6.3(a) of the Agreement is hereby terminated in
its entirety and amended and superseded as follows:

                                       1.

<PAGE>

          "InterMune shall pay to Amgen milestone payments as set forth in this
     Section 6.3(a) within [***] after the first achievement of the
     corresponding milestone for a PEG-Infergen Product that (i) is pegylated
     [***] and/or (ii) is pegylated [***] (in either case, an "Amgen
     PEG-Infergen Product") that is [***] to be [***]

5. The phrase [***] in Item 2 of the Milestone Events table in Section 6.3 (b)
of the Agreement shall be deleted and replaced with the phrase [***]

6. In consideration for Amgen extending the know-how license granted to
InterMune in Section 2.4 of the Agreement to further allow InterMune to use
Amgen Know-How for the sole purposes of [***] in the Territory and for its
convenience, InterMune proposed payment of [***]. Amgen accepted InterMune's
proposal, and [***]. Accordingly, Section 6.5 of the Agreement is hereby
terminated in its entirety and amended and superseded as follows:

     "6.5 TERM OF ROYALTIES. Amgen's right to receive Royalties under Section
6.4 shall expire, on a Licensed Product-by-Licensed Product basis, in each
country of the Territory upon the [***]. Notwithstanding the foregoing sentence,
Amgen shall have the right to receive from InterMune, and InterMune shall be
obligated to pay to Amgen, Royalties for any PEG-Infergen Product [***];
provided, however, that InterMune's obligation to pay Royalties for any
PEG-Infergen Product [***] shall [***] if and [***] as a [***] at [***] in any
[***] that is a [***]

7. This Amendment shall be deemed to amend terms of the Agreement pursuant to
Section 15.1 thereof and the Agreement, as amended and modified by this
Amendment, shall remain in full force and effect and shall constitute the
complete, final and exclusive understanding and agreement of the parties
respecting the subject hereof and thereof.

8. Whenever possible, each provision of this Amendment shall be interpreted in
such a manner as to be effective and valid under applicable law, but should any
provision of this Amendment be held to be prohibited or invalid under applicable
law, such provision shall be ineffective only to the extent of such prohibition
or invalidity, without invalidating the remainder of this Amendment.

9. This Amendment shall be governed by and interpreted in accordance with the
substantive laws of the State of California and the Parties hereby submit to the
jurisdiction of the California courts, both state and federal.

10. No amendment, modification or supplement of any provision of this Amendment
shall be valid or effective unless made in writing and signed by a duly
authorized officer of each Party.

11. This Amendment may be signed in any number of counterparts, each of which
shall be an original, with the same effect as though the signatures hereto and
thereto were on the same instrument.

12. This Amendment No. 1 to the Agreement is made effective as of April 25,
2002.

                                             ***Confidential Treatment Requested

                                       2.

<PAGE>

IN WITNESS THEREOF, the parties have executed this Amendment No. 1 to the
Agreement as of the date(s) set forth below.

INTERMUNE, INC.                         AMGEN INC.

By: /s/ Stephen Rosenfield               By: /s/ Scott Foraker
    ----------------------------------       -----------------------------------
Print Name: Stephen N. Rosenfield       Print Name: Scott J. Foraker
Title: Senior Vice President of Legal   Title: VP Licensing
       Affairs and General Counsel

Date: 4/                                Date: 4/24/02
        --------------------

                                       3.<PAGE>

                                                                   EXHIBIT 10.30

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                    WITH THE SECURITIES AND EXCHANGE COMMISSION.
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(B)(4)
                                                                  AND 240.24B-2.

(INTERMUNE (R) LOGO)

December 31, 2004

Thomas D. Zindrick
Vice President, Law
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

RE:  AMENDMENT NUMBER 2 TO AMGEN/INTERMUNE LICENSE AND COMMERCIALIZATION
     AGREEMENT FOR INFERGEN

Dear Mr. Zindrick:

As you know, Amgen Inc. ("Amgen") and InterMune, Inc. ("InterMune") are parties
to that certain License and Commercialization Agreement effective June 15, 2001,
as first amended April 25, 2002 (the "Agreement"). The Parties have now agreed
to amend the Agreement to provide for the transfer of certain Amgen technology
for manufacturing Infergen to InterMune and/or InterMune's contract
manufacturer[***] in accordance with the terms set forth in this letter
amendment (the "Amendment").

Therefore, for good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Parties hereby agree to amend the Agreement
pursuant to this Amendment as follows:

1.   This Amendment is effective as of the Amendment Effective Date. Capitalized
     terms used herein and not otherwise defined will have the same meaning as
     ascribed thereto in the Agreement.

2.   The following capitalized terms will have the meanings set forth below:

     (a)  "Allowed Activities" means use on and after the Amendment Effective
          Date by InterMune, its Affiliates, its assignees and/or its Authorized
          Sublicensees, in accordance with this Amendment, of the Manufacturing
          Process and any improvements thereto developed by InterMune or [***]
          on InterMune's behalf, to develop, manufacture or have manufactured a
          Licensed Product for development, use or sale in the Territory.

     (b)  "Amendment Effective Date" means the date first set forth above.

                                             ***Confidential Treatment Requested

<PAGE>

     (c)  "Amgen Manufacturing Improvements" means any improvements to the
          Manufacturing Process conceived, created or discovered solely by
          Amgen, its Affiliates or its licensees (other than InterMune) after
          the Amendment Effective Date but prior to the expiration of the Term
          or the earlier termination of the Agreement.

     (d)  "Amgen Manufacturing Patents" means all Patents [***]. Amgen
          Manufacturing Patents will be [***] of [***] for all purposes under
          the Agreement.

     (e)  "Amgen Manufacturing Technology" means: (i) the Manufacturing Process;
          (ii) all data, documentation, know-how and trade secrets owned or
          Controlled by Amgen relating to the Manufacturing Process to the
          extent actually provided by Amgen to InterMune under Section 6 of this
          Amendment; (iii) the Amgen Manufacturing Patents; and (iv) the Amgen
          Materials. Amgen Manufacturing Technology excludes any InterMune
          Manufacturing Improvements.

     (f)  "Amgen Materials" means the materials set forth in Exhibit 2 hereto
          and any other material provided to InterMune and/or [***] by Amgen
          pursuant to Section 6.

     (g)  "Authorized Sublicensee" means a sublicensee of InterMune's rights
          pursuant to Section 3 of this Amendment, the sublicense to whom is
          permitted pursuant to Section 3(a) or 3(d) of this Amendment.

     (h)  "[***] Affiliate" will mean an entity that, directly or indirectly,
          through one or more intermediaries, controls, is controlled by, or is
          under common control with [***]. For the purposes of this definition,
          control will mean the direct, indirect or indirect ownership of
          greater than fifty percent (50%) or, if less than fifty percent (50%),
          the maximum percentage as allowed by applicable law of (i) the stock
          shares entitled to vote for the election of directors or (ii)
          ownership interest.

     (i)  "CDA" means the confidentiality and materials transfer agreement
          substantially in the form attached hereto as Exhibit 7 hereto to be
          executed by and among InterMune, Amgen and [***] to enable the
          technology transfer activities described in Section 6 hereof to
          commence.

     (j)  "Contract Manufacturer" means a manufacturer of [***] Licensed Product
          [***] and/or [***] Licensed Product, which manufacturer is [***]
          responsible for such manufacture, although it may [***] to perform
          [***] of the [***] Licensed Products.

     (k)  "GMP" means current Good Manufacturing Practices as defined in the
          United States Code of Federal Regulations (21 CFR 210 and 211 et
          seq.).

     (l)  "Infergen BLA" means the BLA for Infergen and any and all updates and
          supplements thereto.

     (m)  "InterMune Manufacturing Improvements" means any improvements to the
          Manufacturing Process conceived, created or discovered solely by
          InterMune, its

                                             ***Confidential Treatment Requested

<PAGE>

          Affiliates or its sublicensees (other than Amgen) after the Amendment
          Effective Date but prior to the expiration of the Term or the earlier
          termination of the Agreement.

     (n)  "Manufacturing Process" means the manufacturing process for Infergen
          described in the Infergen BLA (i) as it exists as of the Amendment
          Effective Date, e.g., in the CMC section of the BLA and updates to the
          BLA existing as of the Amendment Effective Date (such as annual
          reportable information, GMP requirements, etc.), and (ii) as such
          Infergen BLA may be modified by Amgen at any time after the Amendment
          Effective Date until the successful completion of the transfer of the
          Manufacturing Process to [***] (or another Contract Manufacturer, as
          the case may be) as contemplated in this Amendment.

     (o)  "Manufacturing Sublicense" means a sublicense agreement between
          InterMune and [***], or other Contract Manufacturer, pursuant to which
          InterMune grants [***] or such other Contract Manufacturer a
          sublicense under the license set forth in Section 3 below to contract
          manufacture Licensed Products.

     (p)  "Process-Related Technical Issues" means manufacturing process issues
          and analytical testing issues relating solely to the Manufacturing
          Process identified through GMP compliance investigations as required
          by a Regulatory Authority as "Process Related" and does not include
          issues identified as "Equipment Related" or "Human Error Related."

3.   (a)  Pursuant to and subject to that certain Amendment to License and
          Supply Agreement by and between Amgen and [***] dated [***] and the
          License and Supply Agreement by and between Amgen and [***] dated
          [***] as amended [***] Amgen hereby grants to InterMune during the
          Term of the Agreement a non-exclusive license under the Amgen
          Manufacturing Technology solely for the purposes of InterMune granting
          a sublicense to [***], to solely develop and contract manufacture (and
          perform all associated activities relating thereto) Licensed Products,
          including without limitation Infergen and PEG-Infergen Product in
          [***] solely for/to InterMune and its Affiliates and Sublicensees for
          [***] InterMune and its Affiliates and Sublicensees in the Territory
          (which sublicense will include the right for [***] to use [***]
          Affiliates and subcontractors to perform elements of the [***]
          Licensed Products). Upon the prior written consent of [***] Amgen,
          which consent from Amgen [***] will not be unreasonably withheld or
          delayed, InterMune may grant a sublicense under the foregoing license
          to another Contract Manufacturer [***] the identical rights permitted
          to be granted to [***] pursuant to this Section 3(a)).

     (b)  Amgen hereby grants to InterMune a non-exclusive license under the
          Amgen Manufacturing Technology solely to manufacture and have
          manufactured Licensed Products in the Territory, provided, however,
          that InterMune will not manufacture any Licensed Products or grant any
          rights to any Third Party to manufacture Licensed Products for
          InterMune until and unless Amgen has first granted its consent thereto
          pursuant to Section 3(d) below.

                                             ***Confidential Treatment Requested

<PAGE>

     (c)  Amgen hereby grants to InterMune a non-exclusive sublicense under the
          Existing License Patents solely to import, manufacture and have
          manufactured Infergen in the Territory, provided, however, that
          InterMune will not manufacture any Infergen or grant any rights to any
          Third Party to manufacture Infergen for InterMune until and unless
          Amgen has first granted its consent thereto pursuant to Section 3(d)
          below.

     (d)  Prior to manufacturing or engaging any Contract Manufacturer (other
          than [***]) to manufacture any Licensed Product, InterMune shall
          provide to Amgen a written request for such manufacturing along with a
          reasonably detailed description of the manufacturing activities, the
          Contract Manufacturer (if applicable), and upon Amgen's reasonable
          request, any other information that would be helpful to Amgen in
          evaluating the then current capabilities of InterMune or such Contract
          Manufacturer and the extent to which such Contract Manufacturer (if
          applicable) is competitive to Amgen. Within [***] days of receiving
          InterMune's request and such supplemental information as Amgen
          requests pursuant to this Section 3(d), Amgen will review such request
          and provide to InterMune its decision about whether to consent to the
          proposed manufacturing activities, which consent will not be
          unreasonably withheld. Once Amgen has approved a sublicense to a
          particular Contract Manufacturer, Amgen's further consent will not be
          required for such Contract Manufacturer to use its affiliates and
          subcontractors to perform elements of the manufacturing, filling and
          finishing of Licensed Products.

     The licenses set forth in this Section 3 are granted [***] or [***] other
     than as set forth in [***] of the Agreement. Notwithstanding any
     sublicensing of InterMune's rights and obligations hereunder to [***] or
     other Authorized Sublicensees, InterMune will remain responsible for the
     full and complete performance of all of InterMune's obligations and duties
     hereunder and under the Agreement. Nothing herein is intended to alter the
     exclusive rights granted to InterMune by Amgen in Article 2 of the
     Agreement. InterMune's licenses set forth this Section 3 will, upon
     expiration of the Agreement as set forth in Section 13.1 thereof,
     automatically convert to being irrevocable and fully-paid.

4.   Amgen hereby covenants that during the period of InterMune's licenses set
     forth in Section 3 hereof, neither Amgen, nor any Amgen Affiliate or
     assignee (the "Amgen Covenantors") will sue InterMune, its Affiliates, its
     assignees and/or Authorized Sublicensees for infringement of any Patent or
     know-how owned or Controlled by any Amgen Covenantor (but excluding the
     Amgen Manufacturing Technology), or under which any Amgen Covenantor has
     the right to sue infringers, solely to the extent InterMune, its
     Affiliates, its assignees and/or its Authorized Sublicensees are performing
     Allowed Activities. The covenant in this Section 4 is expressly subject to
     InterMune's and its Affiliates', assignees' and/or sublicensees' continuous
     compliance with all of the terms and conditions of this Amendment and the
     Agreement.

     For the avoidance of doubt, nothing set forth in the Agreement or this
     Amendment will preclude Amgen from using the Amgen Manufacturing Technology
     or granting a license to the Amgen Manufacturing Technology to a Third
     Party, in each case for: [***].

                                             ***Confidential Treatment Requested

<PAGE>

5.   Amgen will provide InterMune and [***] with access to the [***] Infergen
     BLA. InterMune will be the license holder for the Infergen BLA and any
     supplements thereto. As between Amgen and InterMune, [***] for interacting
     with Regulatory Authorities and for obtaining all necessary Regulatory
     Approvals for the manufacturing of Infergen by [***] for use or sale in the
     Territory.

6.   Amgen will provide support (not to exceed [***] hours for technical support
     and [***] hours of regulatory support, except as set forth herein below) to
     InterMune as requested by InterMune, as solely limited to the following:

     (a)  assisting InterMune in developing a plan to transfer the Manufacturing
          Process (a preliminary form of transfer plan is attached as Exhibit 4
          hereto);

     (b)  assisting InterMune in the transfer of the Manufacturing Process to
          [***]; and

     (c)  providing relevant manufacturing know-how and documentation set forth
          on Exhibit 5 hereto (which Amgen will complete within [***] days from
          the Amendment Effective Date, except for relevant manufacturing
          know-how and documentation set forth on Exhibit 5 hereto that relates
          to tasks and processes currently performed at [***] which Amgen will
          complete within [***] days after the Amendment Effective Date;
          provided, however, that in the event that InterMune provides written
          notice to Amgen of specific know-how and documentation that relates to
          tasks and processes currently performed at [***] and the reason that
          the same is needed prior to the end of such [***] day [***] period
          then Amgen shall use reasonable efforts to endeavor to provide the
          requested know-how and documentation sooner) and such other know-how
          and documentation necessary to manufacture Infergen as InterMune
          reasonably requests, provided that such know-how and documentation
          exists and Amgen would not have to [***] and that Amgen's obligation
          to deliver such know-how and documentation will be limited to Amgen's
          obligations to provide support under this Section 6, and further
          provided that InterMune hereby acknowledges that [***] may not have
          been [***] Amgen and therefore may [***] to be [***] hereunder.

     InterMune acknowledges that Amgen has already expended, but not yet
     invoiced InterMune for, approximately [***] hours of technical support
     expended in [***], which will be deemed deducted from such [***] hours of
     technical support described above. In its sole discretion, Amgen may
     provide additional support beyond the hour limits stated above upon
     InterMune's reasonable request. InterMune and Amgen will each endeavor to
     manage blocks of time for coordinating technical transfer discussions,
     issues and manufacturing site interactions with Amgen and [***] so as to
     minimize [***], in accordance with the preliminary transfer plan attached
     as Exhibit 4 hereto. During the first [***] months and [***] days from the
     Amendment Effective Date, the Parties will hold [***] meetings with the
     appropriate technical personnel from InterMune and Amgen, and at
     InterMune's request, [***], no less than [***] as described in more detail
     in the Communications Plan attached hereto as Exhibit 8. Where practicable,
     such meeting will be held at [***]. Amgen's technical support obligations
     under Sections 6(a), (b) and (c) above with respect to transfer of the
     Manufacturing Process will not extend beyond [***]

                                             ***Confidential Treatment Requested

<PAGE>

     months from the execution of the CDA (the "Initial Support Term"), subject
     to subsection (i) below, and provided that Amgen's obligation to provide up
     to [***] hours of regulatory support will continue until such time as [***]
     receives FDA approval to manufacture bulk and finished Infergen for
     commercial supply.

     Amgen will [***], and InterMune will [***] Amgen under this Section 6 in
     accordance with the Additional Work provision in Exhibit F of the Agreement
     as well as [***] Amgen's [***] including, without limitation, [***]. All
     such [***] will be [***] in accordance with Amgen's then-current [***]
     policy.

     Solely in the event that, prior to InterMune providing a notice to Amgen
     pursuant to Section 14(b) below and prior to InterMune obtaining regulatory
     approval for the production of any Licensed Product at [***], the
     Manufacturing Process transfer is [***] by Process-Related Technical Issues
     that [***] Amgen will:

     (i)  use such efforts as [***] (if any) to render the Manufacturing Process
          transferable, which will be at its own expense once the
          above-mentioned [***] hours of technical support have been utilized;
          and

     (ii) notwithstanding Section 14(a), continue to manufacture and supply
          Infergen on behalf of InterMune as specified in the Agreement prior to
          this Amendment.

     Issues related to changes to the Manufacturing Process by InterMune or
     [***] after the Amendment Effective Date will be deemed not to be
     Process-Related Technical Issues, and will be [***] sole responsibility.

     Each Party will designate in writing to the other Party a project leader,
     which individual will be a person of appropriate experience, skill and
     knowledge to oversee such Party's activities under this Section 6. If any
     dispute between the Parties arises relating to Amgen's provision of support
     under this Section 6, then either Party may give written notice thereof to
     the other Party. Within [***] days of receipt of such notice, the project
     leaders will meet and attempt in good faith to resolve such disputed issue.
     If such project leaders are unable to resolve any such issue within [***]
     days after receipt of such notice, then such issue will be dealt with as
     set forth in Section 14.1 of the Agreement.

7.   (a)  InterMune will obtain a covenant from [***] (and any other Contract
          Manufacturer [***]) that provides that such Contract Manufacturer
          will:

          (i)  during the term of the applicable Manufacturing Sublicense, work
               exclusively with InterMune and/or its Affiliates, assignees
               and/or Sublicensees on the development and contract manufacturing
               of Licensed Product and will not, on its own behalf and/or on
               behalf of a Third Party, enter into any agreement, render
               services or otherwise supply any Licensed Product to any Third
               Party other than InterMune and its Affiliates, assignees and/or
               sublicensees whereby such agreement, service or supply would
               conflict with the exclusivity obligations of such Contract
               Manufacturer set forth hereinabove; and

                                             ***Confidential Treatment Requested

<PAGE>

          (ii) during the term of the [***]: (x) maintain in confidence all
               Amgen Manufacturing Technology to the same extent such Contract
               Manufacturer maintains its own proprietary industrial information
               of similar kind and value (but at a minimum such Contract
               Manufacturer will use commercially reasonable efforts to maintain
               such Amgen Manufacturing Technology in confidence); and (y) keep
               confidential and will not publish or otherwise disclose and will
               not use for any purpose other than such development and contract
               manufacturing for/to InterMune and its affiliates and
               sublicensees Amgen Manufacturing Technology, provided, however,
               that: (A) such Contract Manufacturer will not be restricted by
               the provisions of this sentence with respect to Amgen
               Manufacturing Technology that: (1) is publicly disclosed by [***]
               Amgen, either before or after it becomes known to such Contract
               Manufacturer; (2) was known to such Contract Manufacturer,
               without obligation to keep it confidential, prior to when it was
               received from InterMune or Amgen, as demonstrated by competent
               written proof; (3) is subsequently disclosed to such Contract
               Manufacturer by a Third Party lawfully in possession thereof
               without obligation to keep it confidential; (4) has been publicly
               disclosed other than by [***] Amgen and without breach of an
               obligation of confidentiality with respect thereto; or (5) has
               been independently developed by such Contract Manufacturer
               without the aid, application or use of Amgen Manufacturing
               Technology, as demonstrated by competent written proof; provided,
               however that this clause (5) shall not be interpreted to
               implicate to any extent InterMune Manufacturing Improvements and
               (B) such Contract Manufacturer may disclose Amgen Manufacturing
               Technology to the extent and to the persons and entities as
               required by an applicable law, rule, regulation, legal process,
               court order or the rules of the National Association of
               Securities Dealers or of the FDA or its Canadian equivalents or
               any successor thereto.

          InterMune's obligations under this subsection (a) will expire
          simultaneously with Amgen's obligation to [***] that the above
          covenants be maintained; provided that no such expiration will relieve
          InterMune of its confidentiality obligations under the Agreement.

     (b)  Prior to Amgen commencing the delivery of any Amgen Materials or Amgen
          Manufacturing Technology to or on behalf of InterMune under this
          Amendment, and for so long as subsection (a) remains in effect,
          InterMune will provide to Amgen [***] of [***] necessary to
          demonstrate compliance with all of the obligations of this Section 7
          for [***] governing any [***] which agreement(s) will contain
          provisions required under subsection (a) above. All of the licenses
          granted by Amgen and obligations of Amgen under this Amendment are
          expressly conditioned upon InterMune obtaining the provisions
          described in subsection (a) above of this Amendment and [***] to
          enforce such provisions during the Term.

                                             ***Confidential Treatment Requested

<PAGE>

     (c)  If [***] to [***] by the obligations set forth in Sections 7(a), 7(c)
          and 9 of this Amendment, and InterMune is [***] a suitable [***] then
          InterMune will give Amgen written notice thereof. In such event,
          InterMune will reimburse Amgen for all of its costs incurred in
          performing its obligations under this Amendment, and InterMune may
          thereafter terminate this Amendment upon providing written notice of
          such termination to Amgen.

8.   Amgen retains all rights, title and interest in and to the Amgen Technology
     and Amgen Manufacturing Technology and will have the right to use the
     Manufacturing Process and/or transfer the Manufacturing Process (and/or the
     right to access and reference the Infergen BLA as it exists as of the
     Amendment Effective Date) to one or more Third Parties solely to enable
     such Third Parties to manufacture products that are not Licensed Products
     for any reason and to manufacture products comprising Licensed Products for
     the sole purpose of commercializing such product(s) outside the Territory.

9.   InterMune hereby covenants that it and its Affiliates, assignees and
     sublicensees (collectively, "InterMune Covenantors") will not sue any Amgen
     Covenantor, for infringement of any Patent owned or Controlled by any
     InterMune Covenantor, or under which any InterMune Covenantor has the right
     to sue infringers, in each case claiming any InterMune Manufacturing
     Improvements, with respect to any product containing [***] by any Amgen
     Covenantor thereof for use and/or sale outside the Territory during the
     Term. InterMune will automatically be deemed to have extended the foregoing
     covenant to any licensee of any Amgen Covenantor [***] any product
     containing [***], which licensee has provided to InterMune, in writing, a
     covenant identical to that set forth in Section 11, for so long as such
     licensee's covenant remains in effect.

10.  Amgen will have a complete and unrestricted right to reference the Infergen
     BLA held by InterMune, its Affiliates, assignees and/or sublicensees,
     including all updates and supplements thereto, for the sole purpose of
     manufacturing Infergen for InterMune, its Affiliates, assignees and/or
     sublicensees until the expiration or termination of all of Amgen's
     obligations to manufacture Infergen for InterMune and/or its Affiliates,
     assigns and/or sublicensees, but thereafter Amgen will have no right of
     reference to any updates or supplements to the Infergen BLA filed by
     InterMune or its Affiliates or sublicensees after the Amendment Effective
     Date.

     (a)  Upon termination of the Agreement (except InterMune's termination for
          Amgen's material breach), InterMune will be deemed to have hereby
          granted to Amgen a [***] non-exclusive license, with the right to
          grant sublicenses, under the InterMune Manufacturing Improvements
          (including, without limitation, InterMune Manufacturing Improvements
          conceived, created or discovered by [***] (or any other Contract
          Manufacturer)), solely to the extent necessary to update the
          Manufacturing Process and to use for any filings with Regulatory
          Authorities relating to the Manufacturing Process and for the
          operation of the Manufacturing Process as improved.

     (b)  Nothing in subsection (a) above will require InterMune to provide
          Amgen with access to: (i) [***] developed by or for InterMune or its
          Affiliates or sublicensees,

                                             ***Confidential Treatment Requested

<PAGE>

          or (ii) any confidential or proprietary information of any Third
          Party. Notwithstanding the foregoing, in the event of a Third Party
          claim against Amgen arising from InterMune's use of the Manufacturing
          Process (as improved by any InterMune Manufacturing Improvements),
          InterMune will provide Amgen, at Amgen's expense, access to the
          InterMune Manufacturing Improvements (including but not limited to any
          [***] developed by or for InterMune or its Affiliates or sublicensees)
          solely in order for Amgen to defend against such Third Party claim.

     Nothing in this Section 10 is intended to prevent the Parties from entering
     into one or more separate agreements or arrangements to provide Amgen
     access to any InterMune Manufacturing Improvements on such terms as the
     Parties may agree in their respective sole and absolute discretion.

11.  All Amgen Manufacturing Improvements will be owned solely and exclusively
     by Amgen. Subject to Section 4 above, InterMune will have no right or
     license to any Amgen Manufacturing Improvement. Notwithstanding the
     foregoing, Amgen hereby covenants that no Amgen Covenantor will sue any
     InterMune Covenantor for infringement of any Patent owned or Controlled by
     any Amgen Covenantor, or under which any Amgen Covenantor has the right to
     sue infringers, in each case claiming any Amgen Manufacturing Improvements,
     with respect to any Licensed Product manufactured by any InterMune
     Covenantor thereof for use and/or sale within the Territory during the
     period of InterMune's licenses set forth in Section 3 hereof.

     THE AMGEN MANUFACTURING IMPROVEMENTS ARE PROVIDED "AS IS," AND AMGEN MAKES
     NO REPRESENTATIONS OR WARRANTIES WITH RESPECT TO ANY AMGEN MANUFACTURING
     IMPROVEMENTS, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF TITLE, FITNESS
     FOR PARTICULAR PURPOSE, MARKETABILITY OR NON-INFRINGEMENT OF ANY THIRD
     PARTY PROPRIETARY RIGHT. NO AMGEN COVENANTOR WILL HAVE ANY LIABILITY TO ANY
     INTERMUNE COVENANTOR RELATING TO SUCH INTERMUNE COVENANTOR'S USE OF ANY
     AMGEN MANUFACTURING IMPROVEMENT.

12.  InterMune will have no right of reference to any updates or supplements to
     any BLA for a product comprising [***] filed by Amgen or its Affiliates,
     licensees or sublicensees after the successful completion of the transfer
     of the Manufacturing Process to [***] (or another Contract Manufacturer, as
     the case may be) as contemplated in this Amendment.

     (a)  Upon termination of the Agreement (except Amgen's termination for
          InterMune's material breach), Amgen will be deemed to have hereby
          granted to InterMune a [***], non-exclusive license, with the right to
          grant sublicenses, under the Amgen Manufacturing Improvements, solely
          to the extent necessary to update the Manufacturing Process and to use
          for any filings with Regulatory Authorities relating to the
          Manufacturing Process and for the operation of the Manufacturing
          Process as improved.

                                             ***Confidential Treatment Requested

<PAGE>

     (b)  Nothing in subsection (a) above will require Amgen to provide
          InterMune with access: to (i) any [***] developed by or for Amgen or
          its Affiliates or sublicensees, or (ii) any confidential or
          proprietary information of any Third Party. Notwithstanding the
          foregoing, in the event of a Third Party claim against InterMune
          arising from Amgen's use of the Manufacturing Process (as improved by
          any Amgen Manufacturing Improvements), Amgen will provide InterMune,
          at InterMune's expense, access to the Amgen Manufacturing Improvements
          (including but not limited to any [***] developed by or for Amgen or
          its Affiliates or sublicensees) solely in order for InterMune to
          defend against such Third Party claim.

     Nothing in this Section 12 is intended to prevent the Parties from entering
     into one or more separate agreements or arrangements to provide InterMune
     access to any Amgen Manufacturing Improvements on such terms as the Parties
     may agree in their respective sole and absolute discretion.

13.  InterMune will be [***] for [***] associated with all work Amgen performs
     pursuant to Sections 6 and 14 of this Amendment in accordance with the
     "Additional Work" provisions of Exhibit F of the Agreement. Amgen will
     [***] InterMune no more frequently than [***] for all such work. InterMune
     will [***] within [***] days of receipt.

14.  (a)  In accordance with InterMune's expected Regulatory Approval by [***]
          and subject to Amgen's obligations under Sections 5 and 6 of this
          Amendment, Amgen's commitment to manufacture Infergen pursuant to
          Exhibit F of the Agreement will be changed to the schedule provided
          below, unless InterMune notifies Amgen in writing pursuant to Exhibit
          F, Rolling Forecast section of the Agreement:

          (i)  [***]

          (ii) [***]

          Amgen will provide InterMune with its production schedules and
          inventory reports for Infergen at least [***] for so long as Amgen
          manufactures Infergen for InterMune.

     (b)  If, prior to the dates set forth in subsection (a) above, the Rolling
          Forecast provides for no Infergen to be manufactured, InterMune
          reserves the right to provide written notice to Amgen that Amgen will
          no longer be required to produce [***] Infergen following a specified
          date (an "End Date"). In any event, InterMune shall also have the
          right to provide [***] month written notice to Amgen that Amgen will
          no longer be required to produce [***] Infergen following a specified
          date (also, an "End Date"). Upon the earlier of Amgen's receipt of
          either type of written notice described in this Section 14(b) or
          InterMune's receipt of Regulatory Approval for [***] or other Contract
          Manufacturer to manufacture Infergen for commercial use in the
          Territory, Amgen shall automatically and irrevocably be released of
          all obligations to manufacture, supply and/or provide

                                             ***Confidential Treatment Requested

<PAGE>

          assistance relating thereto following an applicable End Date or the
          date of InterMune's receipt of Regulatory Approval; provided, however:

          (i)  at InterMune's written request, Amgen shall complete any
               then-current work-in-progress and InterMune shall promptly take
               all necessary actions, with Amgen's reasonable cooperation, to
               remove Amgen's name from the Infergen BLA; and

          (ii) unless otherwise requested in writing by InterMune, Amgen will
               remain responsible for continuing to perform all on-going
               regulatory obligations required of pharmaceutical manufacturers
               by the FDA for all Infergen manufactured by Amgen for InterMune,
               including without limitation stability testing. Such work will be
               [***] in accordance with the "Additional Work" provisions of
               Exhibit F of the Agreement.

          Nothing in this subsection (b) is intended to release Amgen from its
          obligations under Section 4.7 of the Agreement or under Sections 5(e),
          6, 11, 12 and 13 of the [***].

     (c)  The work described in subsections (b)(i) and (ii) above will be [***]
          in accordance with the "Additional Work" provisions of Exhibit F of
          the Agreement.

     (d)  Notwithstanding InterMune obtaining Regulatory Approval for [***] or
          other Contract Manufacturer to manufacture Infergen, InterMune shall
          remain obligated to purchase remaining [***] Infergen manufactured, or
          in the process of being manufactured, by Amgen, based on the Rolling
          Forecast. Concurrently with Amgen's final invoice for such Infergen,
          Amgen shall deliver to InterMune an invoice for a [***] (or [***] as
          applicable) representing the [***] between the [***] for [***]
          Infergen and [***] Infergen charged to InterMune based on the
          then-established [***] for the last applicable fiscal year (based on
          Amgen's fiscal year), or portion thereof and Amgen's actual [***] for
          manufacturing Infergen for the same period. Such [***] (or [***] as
          applicable) will not include the [***] for any work for which Amgen
          [***] InterMune under the "Additional Work" provisions of Exhibit F of
          the Agreement.

15.  The forecast for [***] Infergen and [***] for the next [***] quarters
     attached hereto as Exhibit 6 (the "New Forecast") will have the effect of
     replacing the previous Rolling Forecast provided by InterMune under the
     Agreement for each quarter so forecasted.

16.  Each Party hereby confirms to the other Party that the indemnity and
     insurance obligations set forth in Sections 10.2 and 10.3 of the Agreement
     remain in full force and effect and will apply to all of the
     responsibilities under the Agreement, including the manufacture,
     distribution, marketing and sale of Licensed Products. InterMune further
     agrees that beginning on the date InterMune (or its Affiliates, assignees,
     sublicensees, subcontractors, co-promoters/co-marketers and distributors)
     first offers for sale a Licensed Product not manufactured by Amgen,
     InterMune will maintain product liability insurance with reasonable
     deductibles and aggregate coverage limits for the Licensed

                                             ***Confidential Treatment Requested

<PAGE>

     Products no lower than [***] U.S. dollars [***] which limits are not
     intended to be construed as (x) a limit to the obligations set forth in
     Section 10.3 of the Agreement, (y) a measure of adequate insurance to cover
     InterMune's obligations under the Agreement, nor (z) a limit to the
     InterMune's liability with respect to indemnification obligations under the
     Agreement.

17.  Amgen hereby represents and warrants that Amgen has sufficient rights in
     and to the Amgen Manufacturing Technology and the Amgen Technology to grant
     the rights set forth in this Amendment.

Except as expressly stated herein, all terms and conditions of the Agreement
will remain in full force and effect.

If you are in agreement with the terms of this Amendment, please have an
authorized representative of your company sign the two (2) enclosed originals,
and return them to the attention of [***] at InterMune. We will return one fully
executed original for your records.

Sincerely,

/s/ Daniel Welch
-------------------------------------
Daniel G. Welch
President and CEO
InterMune, Inc.

Accepted and Agreed:

AMGEN INC.

By: /s/ T.D. Zindrick
    ---------------------------------
Name: Thomas D. Zindrick
Title: Vice President, Law

Date: 1/13/2005

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 1

                           AMGEN MANUFACTURING PATENTS

<PAGE>

                                    EXHIBIT 1

                 AMGEN CONSENSUS INTERFERON PATENTS/APPLICATIONS

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 2

                                 AMGEN MATERIALS

<PAGE>

                                    Exhibit 2

                                 Amgen Materials

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 3

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 4

                            PRELIMINARY TRANSFER PLAN

<PAGE>

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 5

                                  DOCUMENTATION

<PAGE>

                                    EXHIBIT 5

                                  DOCUMENTATION

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 6

                                    FORECAST

<PAGE>

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 7

                                   FORM OF CDA

<PAGE>

                        CONFIDENTIAL DISCLOSURE AGREEMENT

                                      [***]

                                             ***Confidential Treatment Requested

<PAGE>

                                    EXHIBIT 8

                               COMMUNICATIONS PLAN

<PAGE>

                               COMMUNICATION PLAN

                                      [***]

                                             ***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]